Fiche publication


Date publication

janvier 2023

Journal

STAR protocols

Auteurs

Membres identifiés du Cancéropôle Est :
Dr ROMIER Christophe


Tous les auteurs :
Guerra-Slompo EP, Picchi-Constante GFA, Marek M, Romier C, Sippl W, Zanchin NIT

Résumé

Here, we describe a combined in cellulo and in vivo approach to identify compounds with higher potential for efficient inhibition of Trypanosoma cruzi. Phase I of in cellulo assays is designed to exclude inactive or toxic compounds, while phase II is designed for accurate IC, CC, and selective index (SI) determination. Compounds showing high SI are tested using in vivo infection models in parallel with benznidazole to assess their efficacy relative to a reference drug used for Chagas disease treatment. For complete details on the use and execution of this protocol, please refer to Marek et al. (2021)..

Mots clés

Cell Biology, Cell-based Assays, High-throughput Screening, Microbiology, Model Organisms

Référence

STAR Protoc. 2023 01 24;4(1):102058